<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929016</url>
  </required_header>
  <id_info>
    <org_study_id>DNDi-0690-01</org_study_id>
    <secondary_id>2018-002021-35</secondary_id>
    <secondary_id>QSC200932</secondary_id>
    <nct_id>NCT03929016</nct_id>
  </id_info>
  <brief_title>Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the&#xD;
      body and will also look at the safety and tolerability of the test medicine after a single&#xD;
      dose. This is the first time the test medicine DNDI-0690 will be administered to humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DNDI-0690 is intended to be used as oral treatment for Visceral Leishmaniasis with potential&#xD;
      for the cutaneous form of the disease, Cutaneous Leishmaniasis. The present protocol&#xD;
      describes the first-in-human (FIH) study with DNDI-0690.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">July 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single Ascending Dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Occurrence of Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>from baseline up to 7-10 days post-dose</time_frame>
    <description>number of subjects experiencing TEAEs classified by MedDRA (Medical Dictionary for Regulatory Activities) System Organ Class and Preferred Terms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes in 12-lead electrocardiogram (ECG) parameters</measure>
    <time_frame>from baseline up to 7-10 days post-dose</time_frame>
    <description>corrected QT interval by Frideriecia's formula (QTcF) (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function</measure>
    <time_frame>from baseline up 7-10 days post-dose</time_frame>
    <description>aspartate aminotransferase (AST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function</measure>
    <time_frame>from baseline up 7-10 days post-dose</time_frame>
    <description>alanine aminotransferase (ALT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function</measure>
    <time_frame>from baseline up 7-10 days post-dose</time_frame>
    <description>creatinine (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function</measure>
    <time_frame>from baseline up 7-10 days post-dose</time_frame>
    <description>creatinine clearance (CLcr)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of DNDI-0690 by Assessing the Changes of Troponin I as a cardiac safety marker</measure>
    <time_frame>4h, 9h, 24h and 48h post-dose</time_frame>
    <description>Troponin I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>pre-dose up to 72 hours post-dose</time_frame>
    <description>To assess plasma pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax)</measure>
    <time_frame>pre-dose up to 72 hours post-dose</time_frame>
    <description>To assess plasma pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>pre-dose up to 72 hours post-dose</time_frame>
    <description>To assess plasma pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-life (T1/2)</measure>
    <time_frame>pre-dose up to 72 hours post-dose</time_frame>
    <description>To assess plasma pharmacokinetic parameters</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <condition>Cutaneous Leishmaniases</condition>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 10mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 10mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo male fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose placebo male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 30mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 30mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 150mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 150mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 400mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 400mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 1200mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1200mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 male 3600mg fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 3600mg male fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo male fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo male fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 400mg male fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 400mg male fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo female fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo female fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active DNDI-0690 1200mg female fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1200mg female fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNDI-0690</intervention_name>
    <description>capsules of 10, 100 and 200 mg</description>
    <arm_group_label>Active DNDI-0690 1200mg female fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 400mg male fed</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 10mg fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 1200mg fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 150mg fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 30mg fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 3600mg fasting</arm_group_label>
    <arm_group_label>Active DNDI-0690 male 400mg fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of DNDI-0690</intervention_name>
    <description>capsules of matching placebo</description>
    <arm_group_label>Placebo female fasting</arm_group_label>
    <arm_group_label>Placebo male fasting</arm_group_label>
    <arm_group_label>Placebo male fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males (Cohorts 1 to 7) or healthy WONCBP (Cohort 8)&#xD;
&#xD;
          -  18 to 55 years (Cohorts 1 to 7) or 18 to 60 years (Cohort 8)of age at the time of&#xD;
             signing informed consent&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 30.1 kg/m2 as measured at screening&#xD;
&#xD;
          -  General good physical health determined by medical and surgical history, physical&#xD;
             examination, 12-lead ECG, vital signs and clinical laboratory tests&#xD;
&#xD;
          -  Normal blood pressure: Systolic blood pressure between ≥90 and ≤140 mmHg, Diastolic&#xD;
             blood pressure ≤90 mmHg, measured after 10 min rest in supine position at screening,&#xD;
             admission and pre-dose&#xD;
&#xD;
          -  A resting Heart Rate (HR) between ≥40 and ≤90 bpm measured after 10 min rest in supine&#xD;
             position at screening, admission and pre-dose&#xD;
&#xD;
          -  ECG recording without clinically significant abnormality, including QTcF measure of&#xD;
             ≤450 msec (male) or ≤470 msec (female) at screening, admission and pre-dose&#xD;
&#xD;
          -  Having had no febrile seizures or infectious illness for at least 7 days prior to&#xD;
             administration of the Investigational Medicinal Product (IMP)&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Must agree to adhere to the contraception requirements and life-style restrictions&#xD;
             defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the 3 months or&#xD;
             90 days prior to Day 1&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study and/or have received&#xD;
             DNDI-0690 previously&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Demonstrating excess in caffeine/xanthine consumption (more than 6 cups of coffee or&#xD;
             equivalent a day)&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
             (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of&#xD;
             wine, depending on type). As confirmed by a positive alcohol breath test at screening&#xD;
             or admission&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months. As confirmed by a&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          -  Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          -  Females of childbearing potential including those who are pregnant or lactating (all&#xD;
             female subjects must have a negative serum pregnancy test at screening and admission).&#xD;
             A woman is considered of childbearing potential unless she is permanently sterile&#xD;
             (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, bilateral tubal&#xD;
             occlusion and bilateral oophorectomy) or is postmenopausal (had no menses for 12&#xD;
             months without an alternative medical cause and a serum follicle stimulating hormone&#xD;
             [FSH] concentration ≥40 IU/L)&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator or delegate at screening&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis&#xD;
             (especially aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma&#xD;
             glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), creatinine, and blood urea&#xD;
             nitrogen (BUN)) as judged by the investigator (laboratory parameters are listed in&#xD;
             Appendix 1). Subjects with Gilbert's syndrome are allowed&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Evidence of renal impairment at screening or admission, as indicated by an estimated&#xD;
             creatinine clearance (CLcr) of &lt;80 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, neurological&#xD;
             (especially seizures), immunological, psychiatric, myopathies, bleeding tendency,&#xD;
             respiratory and particularly gastrointestinal (GI) disease, especially peptic&#xD;
             ulceration and chronic gastritis, GI bleeding, ulcerative colitis, Crohn's Disease or&#xD;
             Irritable Bowel Syndrome, as judged by the investigator&#xD;
&#xD;
          -  History of additional risk factors for Torsades des Pointe (eg heart failure,&#xD;
             hypokalaemia, family history of long QT syndrome)&#xD;
&#xD;
          -  Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or&#xD;
             sucrose-isomaltase insufficiency&#xD;
&#xD;
          -  Any relevant GI complaints within 7 days of dosing&#xD;
&#xD;
          -  Subjects with a history of cholecystectomy or gall stones (Cohort 7 only)&#xD;
&#xD;
          -  Serious adverse reaction or clinically relevant hypersensitivity to any drug or the&#xD;
             formulation excipients (Hypromellose [HPMC], sodium lauryl sulphate [SLS], sucrose,&#xD;
             croscarmellose sodium and magnesium stearate)&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment (including&#xD;
             asthma, urticaria, clinically significant allergic rash or other severe allergic&#xD;
             diathesis), as judged by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
          -  Donation or loss of greater than 500 mL of blood within the previous 3 months or more&#xD;
             than 100 mL within 30 days before signing Informed Consent Form (ICF) to this trial&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug&#xD;
             (including anti-acid drugs) or vitamins/herbal remedies (eg St. John's Wort and others&#xD;
             which are known to interfere with the Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein&#xD;
             (P-gp) metabolic pathways) or HRT in the 21 days before IMP administration.&#xD;
             Administration of up to 4 g of paracetamol per day within 7 days of IMP administration&#xD;
             is allowed&#xD;
&#xD;
          -  Surgery within 12 weeks prior to screening, with the exception of appendectomy&#xD;
&#xD;
          -  Any surgery (eg gastric bypass) or medical condition that may affect absorption of&#xD;
             orally administered drugs&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-human</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in the publication will be shared at the time of publication of study results.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>at the time of publication of study results.</ipd_time_frame>
    <ipd_access_criteria>not yet defined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

